Satellos Bioscience has announced that its investigational Duchenne muscular dystrophy (DMD) treatment SAT-3247 has officially received the International Nonproprietary Name (INN) Forazapadin from the World Health Organization (WHO). The naming milestone is an important step in the drug’s global clinical development and future regulatory pathway.
Table of Contents
What is Forazapadin?
Forazapadin is an oral small-molecule medicine being developed to improve muscle regeneration in people living with Duchenne muscular dystrophy. Unlike gene therapies or exon-skipping treatments, Forazapadin works through a dystrophin-independent mechanism, meaning it is designed to be used regardless of a patient’s exon mutation or genetic subtype.
The drug targets a protein called AAK1, which plays a role in the body’s natural muscle repair process. Satellos believes blocking AAK1 may help restore muscle regeneration that is disrupted in Duchenne muscular dystrophy.
Why the WHO Name Matters
An International Nonproprietary Name (INN) is the official generic name assigned through the WHO naming process. Receiving an INN indicates that a therapy has reached a more advanced stage of development and provides a globally recognized name that can be used consistently in scientific publications, clinical trials, regulatory submissions, and future commercialization.
Going forward, Satellos says it will gradually replace the name SAT-3247 with Forazapadin in its scientific and regulatory communications.
Phase 2 Clinical Trials Continue
Forazapadin is currently being evaluated in two Phase 2 clinical studies for Duchenne muscular dystrophy:
- BASECAMP — a randomized, placebo-controlled global study in children with DMD.
- TRAILHEAD — an open-label Phase 2 study in adults with DMD.
According to Satellos, enrollment in the BASECAMP trial is expected to be completed during the current quarter, while the first clinical data from the study is expected in the fourth quarter of 2026. Learn More: Explore Duchenne Clinical Trials
The company also plans to begin a Phase 2 clinical trial of Forazapadin in facioscapulohumeral muscular dystrophy (FSHD) before the end of 2026.
Why This Could Be Important for the DMD Community
Most current DMD therapies target specific genetic mutations or focus on restoring dystrophin. Forazapadin is being developed with a different goal: supporting the body’s ability to regenerate skeletal muscle, independent of dystrophin production.
If successful in clinical trials, this approach could potentially be used:
- Across different Duchenne mutation types.
- Alongside other approved DMD therapies.
- As a standalone treatment aimed at preserving muscle health.
However, it is important to note that Forazapadin remains an investigational medicine. Its safety and effectiveness are still being evaluated in ongoing clinical trials, and it has not yet received regulatory approval for Duchenne muscular dystrophy.
DMDWarrior’s Take
The assignment of the name Forazapadin is not an approval, but it is a meaningful milestone that reflects the maturity of Satellos’ Duchenne development program. DMDWarrior will continue to closely follow the BASECAMP and TRAILHEAD clinical trials and report new efficacy, safety, and biomarker updates as they become available.
Are You Eligible for Forazapadin? Check Now!
